好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Changes in Vestibular Ocular Motor Screen in Adolescents Treated with Vestibular Therapy after Concussion
Neuro Trauma, Critical Care, and Sports Neurology
S30 - Sports Neurology and Neuro Trauma (3:42 PM-3:54 PM)
002

To examine interrelationships between various Vestibular/Ocular-Motor Screen (VOMS) items, to characterize recovery in VOMS performance in a sample of post-concussion adolescents.

Previous studies indicated that post-concussion vestibular and ocular motor deficits are common with a prevalence ranging from 28% to 90%. It is recognized that vestibular and ocular motor deficits can contribute to many post-concussion symptoms such as dizziness, balance problems, blurred vision, headache, nausea, sensitivity to light, sensitivity to sound, and fogginess. The Vestibular/Ocular-Motor Screen (VOMS) was developed to screen for seven aspects of vestibular and ocular motor impairments after concussion. This is the first study to document that the VOMS tool, originally designed as a screening tool, can capture recovery in vestibular and ocular motor function after concussion. This is the first study to analyze vestibular and ocular motor recovery using VOMS.

Seventy-seven patients with concussion and seventy-seven healthy participants completed the study. Spearman-rho (rs) correlation coefficient was used. Wilcoxon signed rank test and McNemar's test were used to examine changes in VOMS over the course of VPT. Mann-Whitney U and χ2 test were used to compare VOMS scores at the conclusion of VPT to healthy controls.

With the exception of NPC distance, all VOMS items were inter-related (rs=0.42-0.79, p<0.001). Over the course of VPT, significant improvements in VOMS performance were observed, and discharge scores were similar to scores observed in healthy adolescents.


The VOMS test measures moderately related functions and it capture changes over
the course of VPT. Clinicians should consider contextual risk of “false positive” in their
interpretation of VOMS.

Authors/Disclosures

PRESENTER
No disclosure on file
Andrea Almeida, MD (University of Michigan Department of Neurology) Dr. Almeida has nothing to disclose.
Nicholas S. Streicher, MD Dr. Streicher has nothing to disclose.
Michael Popovich, MD (NCAC) Dr. Popovich has nothing to disclose.
Matthew T. Lorincz, MD, PhD (University of Michigan-NCAC Neurology) Dr. Lorincz has received personal compensation for serving as an employee of Alexion. Dr. Lorincz has received personal compensation for serving as an employee of Orphalon . Dr. Lorincz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Lorincz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Orphalon . Dr. Lorincz has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medlink Neurology. The institution of Dr. Lorincz has received research support from Alexion.